https://european-biotechnology.net/wp-content/uploads/2024/09/324EB_von-der-Leyen_tg-1030x687-1.webp6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-18 09:20:452024-09-26 16:32:01Von der Leyen names new EU Commissioners
https://european-biotechnology.net/wp-content/uploads/2024/09/ImmunOS.png404748Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-17 13:17:552024-09-17 13:17:55ImmunOs Therapeutics AG raises US$11m in Series C financing
https://european-biotechnology.net/wp-content/uploads/2024/09/phoremost-team-e1726068886775.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-11 16:01:552024-09-11 16:01:55Phoremost reports Series B extension
https://european-biotechnology.net/wp-content/uploads/2024/09/SOLASTA-Bio-laboratory-002-pic-credit-Andrew-Cawley-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-11 14:29:292024-09-11 14:29:29Funding for green insecticides
https://european-biotechnology.net/wp-content/uploads/2024/09/az-gothenburg-1030x579-1.jpeg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-10 14:05:592024-09-10 14:05:59AZ’s lung cancer drug disappoints
https://european-biotechnology.net/wp-content/uploads/2024/09/Fenebrutinib-wikimedia.org_-e1725436453119.png450800Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-04 07:54:452024-09-04 07:54:45Roche with good interim clinical results
https://european-biotechnology.net/wp-content/uploads/2024/09/Individor-e1725432031394-1030x580-1.jpg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-04 06:41:252024-09-04 06:41:25Individor set to waive AEF0117 licence after Phase IIb failure
